Sugi Predict

Sugi Predict / Targets / P2RX1

P2RX1

P2X purinoceptor 1 · P51575 · P2RX1 on Sugi Atlas →

40,291 patent compounds predicted against P2RX1, 28,329 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL127962 SCHEMBL127962 1.00 18/20
SCHEMBL130064 SCHEMBL130064 0.60 17/20
SCHEMBL132386 SCHEMBL132386 1.00 16/20
SCHEMBL130439 SCHEMBL130439 0.81 16/20
SCHEMBL130210 SCHEMBL130210 0.74 16/20
SCHEMBL130929 SCHEMBL130929 0.74 16/20
SCHEMBL130479 SCHEMBL130479 0.72 16/20
SCHEMBL131701 SCHEMBL131701 0.71 16/20
SCHEMBL136190 SCHEMBL136190 0.70 16/20
SCHEMBL131425 SCHEMBL131425 0.69 16/20
SCHEMBL131907 SCHEMBL131907 0.68 16/20
SCHEMBL129050 SCHEMBL129050 0.67 16/20
SCHEMBL129635 SCHEMBL129635 0.66 16/20
SCHEMBL129733 SCHEMBL129733 0.66 16/20
SCHEMBL129734 SCHEMBL129734 0.66 16/20
SCHEMBL130844 SCHEMBL130844 0.66 16/20
SCHEMBL130845 SCHEMBL130845 0.66 16/20
SCHEMBL128984 SCHEMBL128984 0.62 16/20
SCHEMBL131241 SCHEMBL131241 0.60 16/20
SCHEMBL131669 SCHEMBL131669 0.58 16/20

Clinical trials — most relevant to P2RX1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine PHASE4COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest PHASE4UNKNOWN
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel PHASE4COMPLETED
Reversal of the Anti-platelet Effects of Ticagrelor PHASE4COMPLETED
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease PHASE2/PHASE3COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention. PHASE3WITHDRAWN
Botulinum Toxin Injections for Oral Neuropathic Pain PHASE3COMPLETED
Trimetazidine as an Adjunct to Enhance Clopidogrel Response. PHASE2COMPLETED
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. PHASE2NOT_YET_RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383 PHASE1UNKNOWN
First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160. PHASE1COMPLETED
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults EARLY_PHASE1COMPLETED
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients nanRECRUITING
Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients nanCOMPLETED
An Investigation Into the Mechanism of Inhalation Cough Challenge nanCOMPLETED
ATP and P2X3 Receptor in Chronic Cough nanUNKNOWN
Effect of Botulinum Toxin A on Neurogenic Detrusor Overactivity in Chronic Spinal Cord Injured Patients nanCOMPLETED
Cytokines in Papillon-Lefèvre Syndrome nanCOMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence nanCOMPLETED
P2X7 Receptor, Inflammation and Neurodegenerative Diseases nanCOMPLETED
Suppressive Functions of Regulatory T Cells in Migraine nanNOT_YET_RECRUITING
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy nanENROLLING_BY_INVITATION
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors nanCOMPLETED
Visceral Afferents nanWITHDRAWN
Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis nanRECRUITING
The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder nanCOMPLETED
Neurogenic Mechanisms in Burning Mouth Syndrome nanCOMPLETED
Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RX1 binder may also engage these)

ProteinNameSimilarity
P47824 — 1.000 P47824 →
P51576 — 1.000 P51576 →
Q5E9U1 — 1.000 Q5E9U1 →
P51577 — 0.998 P51577 →
P2RX5 P2X purinoceptor 5 0.997 landscape →
Q9JJX6 — 0.996 Q9JJX6 →
P2RX4 P2X purinoceptor 4 0.995 landscape →
O70397 — 0.986 O70397 →
Q91VE2 — 0.985 Q91VE2 →
O54803 — 0.985 O54803 →
P51579 — 0.984 P51579 →
F8W463 — 0.984 F8W463 →
P49653 — 0.980 P49653 →
P51578 — 0.980 P51578 →
P2RX2 P2X purinoceptor 2 0.980 landscape →
P18597 — 0.980 P18597 →
Q64663 — 0.979 Q64663 →
Q9Z1M0 — 0.979 Q9Z1M0 →
Q202B1 — 0.979 Q202B1 →
Q5T197 — 0.978 Q5T197 →
Q2KJC3 — 0.978 Q2KJC3 →
P2RX3 P2X purinoceptor 3 0.978 landscape →
Q3UR32 — 0.977 Q3UR32 →
Q9UN42 — 0.977 Q9UN42 →
ATP4B Potassium-transporting ATPase subunit beta (G 0.977 landscape →
P2RX7 P2X purinoceptor 7 0.977 landscape →
P49654 — 0.976 P49654 →
A7MB71 — 0.976 A7MB71 →
Q9BDK6 — 0.976 Q9BDK6 →
P18434 — 0.976 P18434 →